Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy
-
- Roche’s exercise of its option concludes initial collaboration and further validates Dyno’s field-leading gene delivery platform and AI-powered sequence design technologies for therapeutic developers
- Dyno to receive option exercise fee of US$7 million with the potential to earn over US$220 million in associated development, regulatory, and commercial milestone payments plus royalties
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ROG; OTCQX: RHHBY) has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. The capsid license is pursuant to the agreement between Dyno and Roche originally announced in May 2020.
Dyno’s platform applies AI and high-throughput in vivo data to solve the most critical challenge facing gene therapy developers: gene delivery. While naturally occurring AAV capsids lack precise targeting to deliver medicine to the right cells, are difficult to manufacture, and have pre-existing immunity, Dyno’s platform navigates the deep sequence space to create synthetic AAV capsids with optimized properties that outperform existing capsids. Dyno’s industry-leading gene delivery solutions thereby enable its partners to develop next-generation gene therapies that can potentially benefit all patients.
“Granting the license of a Dyno capsid to a leading drug development company like Roche is a significant achievement for AI in gene therapy,” said Eric Kelsic, Ph.D., Founder and Chief Executive Officer of Dyno. “This latest advancement in one of our partnerships is further validation of the proven effectiveness of our gene delivery platform and continued and rapid advancement of our sequence design capabilities.”
“Granting the license of a Dyno capsid to a leading drug development company like Roche is a significant achievement for AI in gene therapy. This latest advancement in one of our partnerships is further validation of the proven effectiveness of our gene delivery platform and continued and rapid advancement of our sequence design capabilities.”
Eric Kelsic – CEO of Dyno Therapeutics
